reason report
share resili given monopoli under-penetrated market
bottom line share surprisingli resili today despit
report full earn manag note
januari see patient util increas m/m still
basic flat y/i thu guid toward low end previous
updat guidanc impli ww sale growth rang
base time meaning new data --
announc new support like protect iv exampl --
level nois still seemingli marketplac driven aha
present circul public well product innov
expand sheath expect late inclin
think might multi-quart turnaround still share
get could continu get support monopoli
potenti seemingli larg under-penetrated monopoli
stabil situat assum impella
sale growth acceler throughout everi quarter
stabl vs comp-adjust basi would impli
remain double-digit grower even work adopt
issu support clinic data
compani point educ user non-us base
stock perspect today ralli hold valuat nearli
sale meaning premium vs smid-cap med-tech
group trade sale tough argu
ev/sal multipl would appropri tri assess
valuat inclin think deserv trade
premium long-term given double-digit sale growth profil
gross oper margin profil strong balanc sheet
reiter op pt price target vs prior appli
ev/sal multipl now-low estim
assum current multipl hold steadi continu
believ top-tier sale growth profil profit warrant
multipl premium vs smid-cap coverag univers averag
y/i previous sale
growth y/i impella flat y/i revenu
move y/i reflect stabl
sale growth comp-adjust basi ww given
initi address concern efficaci safeti
impella devic invest on-going clinic trial
lower oper margin estim
medic suppli devic
ev/sal multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu dilut gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target us
much execut stori compani continu drive adopt impella famili
percutan ventricular assist devic pvad enter next phase adopt
curv admittedli like multi-quart turnaround requir heavi lift
compani still believ double-digit growth sustain even period
transit compani like retain monopoli svbl estimate us heart recoveri
market opportun forese futur time-frame project
sale compound-annual-growth-rate drive adopt current high-risk pci cardiogen shock
indic
highli under-penetrated market opportun penetr
base abmd market assess address patient includ
cardiogen shock patient high-risk pci patient right heart failur
patientsal believ remain intact
geograph expans germani japan manag estim
penetr address patient germani still earli commerci
roll-out address patient market opportun japan
clear strateg plan break barrier adopt motto train data
time compani continu train physician build clinic data still
balloon pump use cardiogen shock patient today compar
estim impella implant given balloon pump
deem class devic countri like germani japanmean
actual caus harm usedit seem clear us technolog eventu becom
obsolet impella viabl replac believ barrier adopt
gradual broken awar spread still-build clinic dataset
train continu ramp
believ drive solid double-digit sale growth exist cardiogen
shock high-risk pci indic view potenti indic expans stemi
st-elev myocardi infarct could ultim doubl exist total
address market todaya call option compani recent receiv
fda approv initi stemi triala prospect multi-cent two-arm trial plan
enrol patient undergo treatment stemi heart attack enrol begun
octob expect finish date time frame
beyond double-digit sale growth monopoli pvad space also offer one
compel margin profil coverag univers gross margin
oper margin leverag ultim push oper margin
believ repres uniqu asset smid-cap med-tech
price target appli ev/sal multipl now-low estim
assum current multipl hold steadi continu believ
top-tier sale growth profil profit warrant multipl premium vs smid-cap
coverag univers averag
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
dollar million except per share data
total good sold
research develop expens
consensu incom statement item includ contributor factset
revenu
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
januari trend similar decemb expect
low end
share-bas
pivot compar today standard care immedi reperfus without
ecp expand cardiac power true cathet target three
liter flow ideal pump high-risk pci physician want
anyth larger way pump short
area inflow valv thin soft membran abras
valv ecp deliv design clinic durat
hour fr pump expand fr
bridg
impella btr expect later outer year estim flow l/min
cathet fr pump shorter design durat month year
also wearabl driver allow patient get discharg
hospit impella btr minim invas approach axillari arteri
 jan close final
detail trial fda expect
start second half
 manag expect first patient octob
 octob manag expect
first patient next three week
 februari stemi trial enrol
patient site
plan begin enrol octob
still pre-clin test aug
-a februari first-in-man ecp still
expect
 jan first-in-man ecp expect
 octob manag expect
first patient end march
expand sheath expand collaps around cathet
end
 februari treat
patient expand sheath
